
Cereno Scientific to evaluate IPF drug as PH-ILD treatment
An innovative drug developed to treat idiopathic pulmonary fibrosis (IPF) will now be evaluated as a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). CS014, a HDAC inhibitor developed by biotech company Cereno Scientific, will be studied as a treatment for PH-ILD to address a… Read More


